Holen Sie sich die Stockscreener-App
18.69
1.91%
-0.33
Schlusskurs vom Vortag:
$19.02
Offen:
$19.08
24-Stunden-Volumen:
108.48K
Relative Volume:
0.44
Marktkapitalisierung:
$500.15M
Einnahmen:
$70.32M
Nettoeinkommen (Verlust:
$-6.68M
KGV:
-75.03
EPS:
-0.2491
Netto-Cashflow:
$12.89M
1W Leistung:
+11.05%
1M Leistung:
+9.30%
6M Leistung:
+5.70%
1J Leistung:
+27.79%
1-Tages-Spanne:
$18.50
$19.20
1-Wochen-Bereich:
$16.14
$19.23
52-Wochen-Spanne:
$11.09
$23.00
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Firmenname
Eton Pharmaceuticals Inc
Sektor
Telefon
(847) 787-7361
Adresse
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
18.65 | 510.07M | 70.32M | -6.68M | 12.89M | -0.2491 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.23 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.05 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.64 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
539.69 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-23 | Bestätigt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-01-06 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-06 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-01-04 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-20 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6%What's Next? - MarketBeat
Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday - MarketBeat
Chipmakers Recap: Is Eton Pharmaceuticals Inc still a buy after recent gainsWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Will Eton Pharmaceuticals Inc. stock deliver strong dividend growth2026 Rallies & Daily Volume Surge Signals - Naître et grandir
Retail Surge: Can Eton Pharmaceuticals Inc lead its sector in growth2025 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
HC Wainwright Analysts Boost Earnings Estimates for ETON - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals (NASDAQ:ETON) Given New $30.00 Price Target at Craig Hallum - Defense World
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug - Investing.com Australia
Eton Gains on Acquiring Right to Baby Medicine - Baystreet.ca
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Eton Pharmaceuticals Secures U.S. Rights to HEMANGEOL® for Infantile Hemangioma Treatment, Launching May 1st - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - The Manila Times
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals, Inc. has signed a licensing agreement to successfully acquire the exclusive U.S. marketing rights for Hemangeol oral solution from Pierre Fabre Medicament Sas. - Bitget
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
US FDA approves Eton Pharma's hormonal disorder drug - AOL.com
Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution - GlobeNewswire
ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times
February 2026's Top Growth Companies With Insider Influence - simplywall.st
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn
Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru
Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews
What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st
Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):